Therefore, targeting these differences holds significant promise in that selective eEF1A2 inhibition could treat the neurological disorders caused by EEF1A2 mutations while sparing normal tissues, whereas eEF1A1-specific compounds might address cancers with oxidative stress vulnerabilities. This evidence concerns the gene EEF1A2 and cancer.